Azathioprine
- TRADE NAME: Azamedac; Azamune; Azasan (aaiPharma); Azatrilem; Imuprin; Imuran (Prometheus); Imurek; Imurel; Thioprine
- INDICATIONS: Lupus nephritis, psoriatic arthritis, rheumatoid arthritis, autoimmune diseases, kidney transplant patients
- CLASS: Antimetabolite, Disease-modifying antirheumatic, Purine anaolog, Immunosuppressant
- HALF-LIFE: 12 minutes
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Allopurinol, Aminosalicylates, Balsalazide, Benazepril, Captopril, Chlorambucil, Co-Trimoxazole, Cyclophosphamide, Cyclosporine, Enalapril, Febuxostat, Fosinopril, Hemophilus B vaccine, Imidapril, Lisinopril, Mesalamine, Mycophenolate, Natalizumab, Olsalazine, Quinapril, Ramipril, Ribavirin, Sulfamethoxazole, Trimethoprim, Vaccines, Warfarin
PREGNANCY CATEGORY: D
Patients receiving immunosuppressants, including azathioprine, are at increased risk of developing lymphoma and other malignancies, particularly of the skin.
Please login to see the rest of this drug profile
SKIN
HAIR
NAILS
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
RENAL
HEMATOLOGIC
OTHER
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life Threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric